In This Store
Category:Active Pharmaceutical Ingredients > Digestive System Drugs
Product Name:Ursodeoxycholic acid
CAS No.:128-13-2
Standard:ChP, USP, EP
Price(USD):1~10
Company:Arshine Group Co.,Ltd.
Grade: Pharmaceutical Grade
Factory Location: Block 14, No.100, Luyun Road, Changsha 410205, Hunan, China.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: L/C
Discover the therapeutic wonders of Ursodeoxycholic Acid(CAS No.128-13-2) (UDCA), a remarkable medication known for its efficacy in promoting liver health and managing various hepatobiliary conditions. Sourced from natural bile acids, this potent compound has been extensively studied and trusted by healthcare professionals worldwide. Embrace the power of Ursodeoxycholic Acid to support liver function and improve overall well-being.
What is Ursodeoxycholic Acid?
Ursodeoxycholic Acid, also known as UDCA or ursodiol, is a secondary bile acid found in small quantities in human bile. However, in medicinal formulations, UDCA is derived from synthetic or bear bile sources. It is renowned for its unique properties that aid in reducing cholesterol levels in bile, protecting liver cells, and assisting in the dissolution of certain gallstones.
How Does Ursodeoxycholic Acid Work?
UDCA's mechanism of action revolves around its dual benefits for liver health. Firstly, it helps to promote the flow of bile, reducing cholesterol saturation in the gallbladder, and preventing the formation of cholesterol-based gallstones. Secondly, UDCA exhibits cytoprotective properties, which means it safeguards liver cells from damage, inflammation, and apoptosis, thus supporting overall liver function.
Key Features and Benefits:
Gallstone Management: Ursodeoxycholic Acid is effective in dissolving small cholesterol gallstones, reducing the need for surgical interventions and facilitating a safer, non-invasive approach to gallstone management.
Primary Biliary Cholangitis (PBC): UDCA is the primary treatment for PBC, an autoimmune liver disease. It helps slow disease progression, improve liver function, and enhance patients' quality of life.
Non-alcoholic Fatty Liver Disease (NAFLD): UDCA shows promise in NAFLD treatment, assisting in reducing liver fat content and inflammation, potentially preventing disease progression.
Liver Protection: The cytoprotective properties of Ursodeoxycholic Acid make it an essential component in liver protection and regeneration strategies.
Cholesterol Reduction: UDCA can effectively lower serum cholesterol levels, making it beneficial for individuals with certain cholesterol-related conditions.
Test item |
Test standard |
Test result |
Appearance |
White or almost white crystalline powder, taste bitter, without stink |
Complied |
Identification |
Enterprise Standard |
Complied |
Related Substance |
Lithocholic Acid ≤ 0. 1% Chenodeoxycholic Acid ≤ 1.0% Other Max. Individual Impurity ≤ 0.20% Total Impurity ≤2.0% |
Complied |
Specific Optical Rotation |
+58° - +62° |
+59.3° |
Melting Point |
200℃ -204℃ |
201.0℃-202.6℃ |
Loss on Drying |
≤0.5 % |
0. 10% |
Ignition Residue |
≤ 0. 10% |
0.07% |
Heavy Mental |
≤ 10ppm |
Complied |
Assay (Titration) |
≥ 99.2%— 101.0% |
100.2% |
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: